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The PTEN tumor suppressor gene modulates several Results and discussion
cellular functions, including cell migration, survival, Differentiation of freshly isolated human monocytes to
and proliferation [1] by antagonizing macrophages over several days in culture dramatically in-
phosphatidylinositol 3-kinase (PI 3-kinase)- creases the expression of a number of genes, including
mediated signaling cascades. Mechanisms by which those encoding osteopontin, PPARg, and the metallopro-
the expression of PTEN is regulated are, however, teinase MMP-9 (Figure 1a–c). Concomitant with the in-
unclear. The ligand-activated nuclear receptor creased expression of PPARg is the ability of PPARg
peroxisome proliferator-activated receptor g agonists, such as rosiglitazone, to modulate the expression
(PPARg) [2] has been shown to regulate of certain macrophage genes selectively, including MMP-9
differentiation and/or cell growth in a number of [9]. Rosiglitazone-treated macrophages showed, as ex-
cell types [3, 4, 5], which has led to the suggestion pected, a significant 25% reduction in MMP-9 mRNA
that PPARg, like PTEN [1, 6], could act as a tumor levels (Figure 1c). The same cells, however, also demon-
suppressor. PPARg has also been implicated in anti- strated a substantial 5-fold elevation in PTEN (phospha-
inflammatory responses [7, 8], although downstream tase and tensin homolog deleted from chromosome 10)
mediators of these effects are not well defined. Here, mRNA expression (Figure 1d). The magnitude of the
we show that the activation of PPARg by its increase in PTEN mRNA expression was much larger
selective ligand, rosiglitazone, upregulates PTEN than the 1.65-fold increase in scavenger receptor CD36
expression in human macrophages, Caco2 mRNA (Figure 1e), transcribed from a gene normally
colorectal cancer cells, and MCF7 breast cancer cells. viewed as one of the better markers of PPARg activation
This upregulation correlated with decreased PI [10]. In separate experiments, another selective PPARg
3-kinase activity as measured by reduced ligand, pioglitazone (1 mM), was also shown to increase
phosphorylation of protein kinase B. One macrophage PTEN mRNA levels significantly (data not
consequence of this was that rosiglitazone shown).
treatment reduced the proliferation rate of Caco2
and MCF7 cells. Antisense-mediated disruption of
PPARg expression prevented the upregulation of The upregulation of macrophage PTEN mRNA expres-
PTEN that normally accompanies monocyte sion by rosiglitazone was concentration dependent with
differentiation and reduced the proportion of a calculated EC50 value of z25 nM, in close agreement
macrophages undergoing apoptosis, while with the known affinity of this ligand for PPARg (Figure
electrophoretic mobility shift assays showed that 1f) [11]. By contrast, the expression of SHIP2, a phospho-
PPARg is able to bind two response elements in the inositide 5-phosphatase [12], was not influenced by rosig-
genomic sequence upstream of PTEN. Our results litazone (Figure 1f). This specificity of PPARg-mediated
demonstrate a role for PPARg in regulating PI upregulation of PTEN is compatible with an exclusive
3-kinase signaling by modulating PTEN expression inhibitory role for the 3-phosphatase pathway of PtdInsP3in inflammatory and tumor-derived cells. metabolism, whereas 5-phosphatases, including SHIP2,
control the relative levels of two signaling lipidsAddresses: *Department of Vascular Biology, GlaxoSmithKline, New
Frontiers Science Park North, Harlow, Essex CM19 5AW, UK. (PtdIns(3,4,5)P3 and PtdIns(3,4)P2) [13]. Importantly, in† Department of Biochemistry, University of Dundee, MSI/WTB parallel with the rosiglitazone-stimulated elevation inComplex, Dundee DD1 5EH, Scotland, UK.
PTEN mRNA, there was a large increase in macrophage
Correspondence: Colin H. Macphee PTEN protein levels (Figure 1g) as well as PtdIns(3,4,5)P3
E-mail: colin_h_macphee@sbphrd.com 3-phosphatase activity (Figure 1h). In separate experi-
ments, this enhanced 3-phosphatase activity was demon-Received: 5 December 2000
Revised: 8 February 2001 strated to be immunoprecipitable with anti-PTEN-spe-
Accepted: 26 March 2001 cific antibodies (data not shown). To determine whether
Published: 15 May 2001 the elevated macrophage PTEN protein content affected
signaling downstream of PI 3-kinase, the PtdInsP3-depen-Current Biology 2001, 11:764–768
dent phosphorylation status of PKB [14] was investigated
0960-9822/01/$ – see front matter on the same Western blot (Figure 1g). As macrophage
Ó 2001 Elsevier Science Ltd. All rights reserved. PTEN levels increased upon treatment with rosiglita-
zone, a marked reduction in the amount of phosphorylated
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Figure 1
PPARg activation substantially increases PTEN mRNA, protein, and content. Western blots of total protein extracts were probed with
enzymic activity in human primary macrophages. Monocytes isolated mouse anti-PTEN antibodies (Santa Cruz Biotechnology) and then
from healthy donors were allowed to differentiate into macrophages reprobed with sheep anti-phospho-PKB and anti-total PKB (Upstate
over 4 days in the presence (filled bars) or absence (open bars) of Biotechnology) to confirm equal loading. (h) Representative
1 mM rosiglitazone. mRNA levels of osteopontin (a), PPARg (b), experiment demonstrating enhanced macrophage PtdIns(3,4,5)P3
MMP-9 (c), PTEN (d), and CD36 (e) were quantified on day 4 using 3-phosphatase activity in response to 1 mM rosiglitazone with
the Taqman 59 nuclease assay and normalized to levels found in freshly accompanying PTEN/T-PKB Western blot (insert). PtdIns(3,4,5)P3
isolated monocytes to generate fold induction. (f) The effect of 3-phosphatase activity assays were carried out on human
rosiglitazone concentration (1–1000 nM) on macrophage PTEN and macrophage lysates at 378C for 5 min as described [23]. Data
SHIP2 mRNA levels. (g) Representative Western blot showing the for (a–f) represent means 6 SD from four different monocyte
concentration-dependent effects of rosiglitazone on macrophage preparations. *p , 0.05 versus control.
PTEN, total PKB (T-PKB), and phosphorylated PKB (P-PKB) protein
PKB was apparent, whereas the levels of total PKB protein known subtypes of PPAR, were unchanged (Figure 2d).
PPARd expression, unlike PPARa, was found to increaseremained unchanged. These results point to a precise
inverse relationship between the level of endogenous ex- during monocyte differentiation. PTEN mRNA and pro-
tein content, however, were both significantly reducedpression of PTEN and the activity state of the PI 3-kinase
pathway, and are compatible with the results of studies by PPARgAS, attaining .95% reduction by day 7 (Figure
2c,d). This apparent abolition of PTEN protein levels byinvolving ectopic overexpression of PTEN in a variety of
cells. PPARgAS treatment suggests that PPARg plays a domi-
nant role in the control of this important enzyme in fully
differentiated macrophages.To define further the role of PPARg in regulating PTEN
expression, antisense oligonucleotides (AS) were used
specifically to abolish the increased expression of PPARg The observation that PTEN protein was present in naı¨ve
monocytes, when little if any PPARg is present, suggestsduring monocyte differentiation over a 7 day time course.
Cells receiving control oligonucleotides behaved no dif- an alternative mechanism of control of expression and/or
that significant constitutive expression of the PTEN geneferently to untreated cells (data not shown). PPARgAS
prevented the upregulation of PPARg mRNA, reaching occurs, as might be expected of such a powerful tumor
suppressor. Although levels of PKB were unaffected byaround 90% inhibition after 7 days in culture (Figure
2a). The dramatic increase in osteopontin mRNA that either differentiation or the presence of PPARgAS, the
proportion that was phosphorylated dramatically in-accompanied differentiation, however, was not altered by
PPARgAS (Figure 2b). These data were corroborated by creased in parallel with the loss of PTEN, demonstrating
a clear activation of the PI 3-kinase cascade (Figure 2d).Western blot analysis demonstrating a selective loss of
PPARg protein over 7 days in the presence of PPARgAS, This was confirmed by following apoptosis, as measured
by cellular caspase 9 activity, which showed a significantwhile protein levels of PPARa and PPARd, the two other
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Figure 2
Specific PPARg antisense oligonucleotides
inhibit macrophage PTEN expression and
influence cellular function. Freshly isolated
human monocytes received either control (C)
or antisense (AS) PPARg oligonucleotides
(designed and manufactured by Biognostik,
Germany) at a final concentration of 1 mM and
were incubated in culture for 7 days with
medium changes every 2 to 3 days. The
sequence lengths of antisense PPARg
(sequence ID: 2.01724) and the respective
control (sequence ID: 1.02773) were the
same, as were their G/C contents. mRNA
levels of PPARg (a), osteopontin (b), PTEN
(c), and MMP-9 (f) were monitored at days 1,
4, and 7. (d) Western blot analysis of
PPARgAS-treated macrophages
demonstrating changes in PPARg, PTEN,
and P-PKB protein content but not PPARa,
PPARd, or T-PKB. PPARg antibodies were
purchased from Biomol GMBH, while PPARa
and PPARd antibodies were purchased from
Affinity Bioreagents. (e) PPARgAS-mediated
decrease in caspase 9 activity at day 7.
Caspase activity was measured using a
colorimetric apoptosis detection kit (R&D
Systems). (g) Enhanced MMP-9 release by
PPARgAS-treated macrophages. MMP-9
activity assays were performed on cell
supernates using an MMP-9 ELISA kit (R&D
Systems). Data are means 6 SD from at least
four different monocyte preparations except
for the representative Western blot shown in
(d). *p , 0.05, S versus AS.
reduction of approximately 60% at day 7 in macrophages rosiglitazone influencing the levels of total PKB protein
or indeed of p85a, a subunit of class IA PI 3-kinases [15].incubated with PPARgAS (Figure 2e). Finally, and in
complete contrast to the significant inhibition of macro-
phage MMP-9 expression by rosiglitazone (Figure 1c),
Taken together, our findings have shed new light on howPPARgAS-treated macrophages released significantly
a powerful tumor suppressor protein, PTEN, is regulatedgreater quantities of MMP-9 protein into the culture me-
within cells. Thus far there is little evidence for acutedium, which paralleled a significant increase in mRNA
regulation of PTEN via covalent modifications such aslevels (Figure 2f,g). Both experimental designs confirm
phosphorylation. Phosphorylation of several residues ina role of PPARg in the regulation of MMP-9.
the C terminus of PTEN, possibly mediated by casein
kinase 2, appears to exert only a minor effect on PTEN’s
activity state, but may instead contribute to the stabilityTo investigate whether the tumor suppressive effects of
PPARg agonists in various malignancies might also in- of the protein in vivo [16]. Unlike many other enzymes
involved in the synthesis and metabolism of inositol lipidvolve effects on PTEN, we investigated whether rosiglita-
zone could influence PTEN levels in two tumor lines, signals, PTEN appears to be constitutively active so that
there is a tight inverse relationship between PTEN ex-Caco2 colorectal cancer cells and MCF7 breast cancer
cells. Previous studies have shown other PPARg activators pression levels and the steady state concentration of
PtdInsP3, together with the signaling pathways down-to inhibit proliferation in cultured breast cancer cells [5].
The data in Figure 3 demonstrate that rosiglitazone in- stream of this bioactive lipid. This idea is consistent with
the observation that the inactivation of just one PTENcreased the levels of PTEN protein in parallel to inhib-
iting significantly the rate of proliferation of both cancer allele has an important consequence on cell survival and
proliferation [17]. To confirm further whether PPARgcell lines. Once again, and consistent with our findings
in macrophages, the proportion of PKB that was phosphor- regulation is direct, we have analyzed the promoter region
of the PTEN gene for the presence of peroxisome prolifer-ylated in Caco2 cells decreased in parallel with increasing
expression of PTEN (Figure 3b). This occurred without ator response elements (PPREs). The analysis identified
Brief Communication 767
Figure 3
PPARg activation increases PTEN expression
in both Caco2 and MCF7 cells, and reduces
their rate of proliferation. Caco2 colorectal
carcinoma (a) or MCF7 breast cancer (c)
cells in a 96-well format were seeded at 1000
cells per well in 5% serum, and after 2 hr
were monitored for zero time
methyl[14C]thymidine incorporation as well as
receiving 1 mM rosiglitazone or vehicle.
Cellular thymidine incorporation was then
followed at 12–24 hr intervals and the medium
was changed every 2 days. Cell proliferation
assays were carried out using Cytostar-T hr incubation, Caco2 cells were lysed and PTEN and T-PKB protein were also measured
plates (Amersham Pharmacia) according to PTEN, P-PKB, T-PKB, and p85a protein after 48 hr for MCF7 cells (insert in [c]). *p ,
the manufacturer’s instructions. (b) After a 96 content were assessed by Western blot. 0.01 versus control.
two putative PPARg response elements in 23.3 kb of observed that mice lacking all forms of the PI 3-kinase
regulatory subunit, p85a, were, surprisingly, hypoglyce-sequence (Figure 4a). In order to test whether PPARg
could bind to these putative PPREs, gel retardation analy- mic and displayed increased glucose tolerance, which in-
dicated enhanced insulin sensitivity. A substantial reduc-sis was performed. The data in Figure 4b demonstrate that
both PPREs recognize and bind PPARg. Transcriptional tion in PI 3-kinase function did not, therefore, result in
insulin resistance. Clearly, much is still to be understoodregulation of PTEN expression via PPARg, therefore,
provides a powerful, potentially ubiquitous mechanism about feedback control loops in insulin signaling, but the
modulation of the PI 3-kinase cascade through enhancedfor the tight regulation of basal and agonist-stimulated
components of the PI 3-kinase signaling cascade. PTEN activity may represent one means of maintaining
insulin-stimulated PI 3-kinase activity within physiologi-
cally relevant limits.These findings prompt some immediate considerations
because the thiazolidinedione PPARg agonists, pioglita-
zone and rosiglitazone, have recently been introduced An important feature of these new observations is the
potential implication for the future treatment of cancersas insulin-sensitizing agents for the treatment of type 2
diabetes. The demonstration that PPARg activation can in which PTEN is still functional, since PPARg agonists
may well prove to be effective anti-cancer drugs. Indeed,downregulate PI 3-kinase signaling appears to represent
a paradox because this effect would be expected to inhibit an earlier agent, troglitazone, was recently shown to have
tumor-differentiating properties [20, 21]. Moreover, theinsulin action. Recent findings, however, have indicated
that intense or prolonged PI 3-kinase signaling can be upregulation of PTEN and subsequent dampening of the
PI 3-kinase pathway in inflammatory cells, such as indetrimental to insulin sensitivity. For example, increased
class IA PI 3-kinase function caused insulin resistance in macrophages as demonstrated here, may also explain the
beneficial activities of thiazolidinedione PPARg activators3T3-L1 adipocytes [18]. More recently, Fruman et al. [19]
Figure 4
PPARg binds two PPAR response elements
in the genomic sequence upstream of PTEN.
(a) The genomic sequence upstream of the
PTEN transcription start site contains two
putative PPARg response elements. PPRE1
and PPRE2 correspond to the sequences
spanning 6914 bp to 6953 bp and 8951 bp
to 8990 bp of GenBank accession number
AF067844, respectively. (b) Gel retardation
analysis of in vitro-translated PPARg.
Radiolabeled PPRE1 and PPRE2 were
incubated with nonprogrammed reticulocyte (lane 10), or with a 100-fold excess of the arrow. The [g-32P]ATP probe was incubated
lysate (lanes 1 and 7, respectively) or in the DR1 element from the ApoCIII gene (lanes for 20 min with the programmed/
presence of 1 or 5 ml of PPARg-programmed 5 and 11). Binding of PPARg-programmed nonprogrammed reticulocyte lysate indicated,
reticulocyte lysate alone (lanes 2 and 3, and reticulocyte lysate to the DR1 PPAR synthesized using the ProteinScript II kit
8 and 9, respectively). 5 ml of programmed response element from the ApoCIII gene (Ambion), before free and protein-bound DNA
lysates was also incubated with a 100-fold promoter is shown in lanes 6 and 12. Protein- were separated on 6% DNA retardation gels
molar excess of PPRE1 (lane 4) or PPRE2 DNA complexes formed are indicated with an (Invitrogen).
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